WWC
NBIX icon

Waypoint Wealth Counsel’s Neurocrine Biosciences NBIX Stock Holding History

Waypoint Wealth Counsel’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$378K Sell
2,869
-431
-13% -$57.2K 0.2% 105
2025
Q4 		$468K Buy
3,300
+259
+9% +$37.5K 0.17% 114
2025
Q3 		$427K Buy
+3,041
New +$412K 0.17% 116

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Waypoint Wealth Counsel's NBIX Position: Q1 2026 in Review

Waypoint Wealth Counsel reduced its Neurocrine Biosciences (NBIX) stake by 13% in Q1 2026, selling an estimated $57.2K and leaving 2,869 shares worth $378K. The position accounts for 0.2% of the portfolio, ranked #105.

Waypoint Wealth Counsel first reported a position in NBIX in Q3 2025 and has held it in 3 quarters since. The position peaked at $468K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Waypoint Wealth Counsel held 2,869 shares of Neurocrine Biosciences worth $378K as of Q1 2026.
  • Waypoint Wealth Counsel sold 431 Neurocrine Biosciences shares in Q1 2026, an estimated $57.2K.
  • Neurocrine Biosciences made up 0.2% of Waypoint Wealth Counsel's portfolio in Q1 2026, its #105 holding.
  • Waypoint Wealth Counsel first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Waypoint Wealth Counsel's Neurocrine Biosciences position peaked at $468K in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Waypoint Wealth Counsel's 13F filing for Q1 2026, filed 23 Apr 2026.